Rebuilding momentum in life sciences: Capital markets, innovation and the path forward

The life sciences sector entered 2026 with renewed momentum following a period of market volatility, constrained capital and macroeconomic uncertainty. At the 2026 J.P. Morgan Healthcare Conference and Market Update Dinner, industry leaders from Baker Tilly, J.P. Morgan and the Allen Institute discussed the current biotech market, investment trends and emerging scientific innovations shaping the future of the industry.

The conversation highlighted a cautiously optimistic outlook. Capital markets are reopening selectively, strategic acquisitions are gaining momentum and new translational research initiatives are helping bring breakthrough science closer to commercialization. At the same time, macroeconomic conditions, policy volatility and global competition continue to influence investor sentiment and industry strategy.

While challenges remain, strong scientific innovation combined with improving capital market conditions is positioning the industry for the next phase of growth.

A strengthening biotech market environment

A key theme from the discussion was the improving outlook for biotechnology markets after several challenging years for investors and emerging companies alike. Insights shared from the J.P. Morgan Healthcare Conference indicate that biotech experienced a notable rebound in 2025. For the first time since the COVID-era market surge in 2020, biotech outperformed broader market benchmarks, signaling renewed investor confidence in innovation-driven healthcare companies.

That recovery did not occur evenly. In the first half of 2025, investor skepticism remained high, with even companies reporting positive clinical results facing declining share prices. Expectations had shifted and investors increasingly required clear differentiation, strong clinical outcomes and well-defined development strategies.

Conditions improved in the second half of the year. Investors began rewarding strong clinical catalysts, clinical-stage biotech companies outperformed larger commercial peers and capital formation accelerated through follow-on offerings. These shifts suggest a renewed appetite for risk in biotechnology, particularly when supported by compelling science and credible development strategies.

IPO markets reopening—selectively

After a historically slow year for biotech IPOs in 2025, early indicators suggest a gradual reopening of the public markets in 2026. Industry expectations suggest approximately 20 to 30 biotech IPOs in 2026, provided market conditions remain stable.

While still below peak activity seen during the biotech boom years, a functioning IPO market plays a critical role in the life sciences ecosystem by providing liquidity, establishing valuation benchmarks and enabling venture capital to flow back into earlier-stage companies. Continuing strong aftermarket performance for newly public biotech companies could further strengthen the IPO pipeline in the coming years.

Mergers and acquisitions driving industry growth

While IPO markets are beginning to return, mergers and acquisitions (M&A) remain the most significant driver of activity in the life sciences sector. Many large pharmaceutical companies are approaching significant patent expirations over the next several years, creating pressure to replenish product pipelines and secure new sources of growth. As a result, large pharma is actively pursuing acquisitions and partnerships with biotechnology innovators.

Several factors are supporting continued M&A activity:

• Major patent cliffs across pharmaceutical portfolios
• Strong balance sheets among large pharma companies
• Continued demand for differentiated assets and innovative platforms
• Potential interest rate stabilization improving financing conditions

Recent transactions include both large-scale acquisitions and smaller “bolt-on” deals focused on promising late-stage or commercial assets. At the same time, interest is growing in earlier-stage technologies and platform-based innovations that may shape future therapeutic development. For emerging biotech companies, strategic partnerships often serve as the gateway to potential acquisitions. Business development conversations can evolve quickly into M&A discussions, making careful positioning and preparation increasingly important.

Innovation trends shaping the sector

Beyond capital markets, the discussion also highlighted several scientific areas that continue to attract significant investor attention. These include oncology, obesity and metabolic disease and precision medicine approaches targeting rare diseases. These areas combine significant unmet medical needs with the potential for large market impact.

Platform-based companies, such as those developing gene therapies, novel biologics or advanced computational drug discovery technologies, face unique valuation challenges. Without a single defined product path, these companies must demonstrate the broader potential of their platforms while managing investor expectations around timelines and commercialization strategies. Across the industry, companies are increasingly focused on aligning scientific innovation with clear strategic and financial pathways to commercialization.

Translating science into opportunity

Another theme highlighted during the discussion was the growing importance of translating academic discoveries into commercial ventures.

One example is the SeaBridge Initiative, part of the Seattle Hub for Synthetic Biology. The initiative is designed to accelerate the commercialization of emerging research by supporting scientists as they transition discoveries from the laboratory into startup formation. Through mentorship, training and incubation resources, the program connects researchers with translational leaders who help guide commercialization strategies and company development. Research supported through the initiative includes technologies that allow cells to record biological signals directly into DNA, providing new insight into how cells respond to disease signals over time and potentially enabling more targeted therapeutic approaches.

Programs like SeaBridge reflect a broader trend across the life sciences sector: increasing focus on bridging the gap between academic research and investor-backed company creation.

Policy and global competition

Despite improving market conditions, macroeconomic and policy factors remain important considerations. Interest rates, inflation and geopolitical developments all influence investor sentiment and capital availability. Regulatory stability is also critical for biotech companies navigating long development timelines and complex approval processes. Many organizations are strengthening governance, compliance and enterprise risk frameworks with risk advisory support to address these evolving pressures.

Another notable trend is the growing role of China in global biotechnology innovation. An increasing number of pharmaceutical assets licensed by global companies are originating from Chinese biotech firms reflecting continued investment in research capabilities and regulatory infrastructure. For U.S. life sciences companies, this evolving global landscape highlights the importance of monitoring international innovation hubs, evaluating partnership opportunities and developing strategies that account for regulatory complexity and global competition.

Looking ahead

The life sciences industry appears to be entering a more constructive phase following several years of market adjustment. Capital markets are reopening, strategic buyers are actively pursuing innovation and new translational initiatives are helping bridge the gap between academic discovery and company formation. While uncertainty remains, from macroeconomic policy to regulatory dynamics, the industry’s underlying drivers remain strong.

As organizations navigate evolving market conditions and strategic opportunities, guidance can help companies evaluate capital options, transactions and long-term growth strategies. Baker Tilly works with organizations across the life sciences industry to help address these challenges and position for what’s next.